| 영문 | mineralocorticoid | 한글 | 염류코르티코이드, 광물코르코이드 |
|---|---|---|---|
| 설명 | 부신겉질에서 나오는 호르몬중의 하나. 이 호르몬은 사람의 광염(또는 전해질: mineral salts, or electrolytes)의 양을 조절하는 가장 중요한 인자다. 이들은 체내에 존재하는 물과 이온양을 조절함으로써, 이른바 적당한 체내환경을 만들어 주는 것이다. 이중 가장 중요한 호르몬은 알도스테론으로 기능은, 콩팥에서 나트륨의 흡수를 증가시키고, 칼륨의 배설을 촉진함으써 체내 수분의 양을 조절한다. |
||
| MC | mass casualties; mast cell; Master of Surgery [Lat. Magister Chirurgiae]; maximum concentration; Med... |
|---|---|
| M-C | mineralocorticoid |
| CCA | Calcium channel antagonists |
|---|---|
| H(2)RA | H(2) receptor antagonists |
| LTRA | Leukotriene receptor antagonists |
| AIIRA | angiotensin II receptor antagonists |
| AME | Apparent Mineralocorticoid Excess |
| receptors, mineralocorticoid | Cytoplasmic proteins that specifically bind mineralocorticoids and mediate their cellular effects. The receptor with its bound ligand acts in the nucleus to induce transcription of specific segments of DNA. Mineralocorticoids were named for their actions on extracellular electrolyte concentrations. The most important example is aldosterone. (12 Dec 1998) |
|---|---|
| mineralocorticoid | 1. <biochemistry> Any of the group of C21 corticosteroids, principally aldosterone, predominantly involved in the regulation of electrolyte and water balance through their effect on ion transport in epithelial cells of the renal tubules, resulting in retention of sodium and loss of potassium, some also possess varying degrees of glucocorticoid activity. Their secretion is regulated principally by plasma volume, serum potassium concentration and angiotensin II and to a lesser extent by anterior pituitary ACTH. 2. <pharmacology> Of, pertaining to, having the properties of or resembling a mineralocorticoid. (12 Jan 1998) |
| hormone, mineralocorticoid | A group of hormones, the most important being aldosterone, that regulate the balance of water and electrolytes (ions such as sodium and potassium) in the body. The mineralocorticoid hormones act specifically on the tubules of the kidney. (12 Dec 1998) |
| adrenergic alpha-antagonists | Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (12 Dec 1998) |
| adrenergic antagonists | Drugs that bind to but do not activate adrenergic receptors. Adrenergic antagonists block the actions of the endogenous adrenergic transmitters epinephrine and norepinephrine. (12 Dec 1998) |
| adrenergic beta-antagonists | Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrythmias, angina pectoris, glaucoma, migraine headaches, and anxiety. (12 Dec 1998) |
| aldosterone antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of aldosterone. (12 Dec 1998) |
| androgen antagonists | Compounds which inhibit or antagonise the biosynthesis or actions of androgens. (12 Dec 1998) |
| gaba antagonists | Drugs that bind to but do not activate gaba receptors, thereby blocking the actions of endogenous gaba or gaba agonists. (12 Dec 1998) |
| cholinergic antagonists | Drugs that bind to but do not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. (12 Dec 1998) |
| muscarinic antagonists | Drugs that bind to but do not activate muscarinic cholinergic receptors (receptors, muscarinic), thereby blocking the actions of endogenous acetycholine or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. Antagonists that discriminate among the various muscarinic receptor subtypes and might allow better control of peripheral and central actions are under development. (12 Dec 1998) |
| heparin antagonists | Coagulant substances inhibiting the anticoagulant action of heparin. (12 Dec 1998) |
| prostaglandin antagonists | Compounds that inhibit the action of prostaglandins. (12 Dec 1998) |
| histamine antagonists | Drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonist. Classical antihistaminics block the histamine h1 receptors only. (12 Dec 1998) |
| histamine h1 antagonists | Drugs that selectively bind to but do not activate histamine h1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonise or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system h1 receptors are not as well understood. (12 Dec 1998) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|